Long-acting beta 2 -agonist in addition to tiotropium versus either tiotropium or long-acting beta 2 -agonist alone for chronic obstructive pulmonary disease (Review)
T A B L E O F C O N T E N
The secondary outcome of pre-bronchodilator FEV 1 showed a small mean increase with the addition of long-acting beta 2 -agonist (MD 0.07 L; 95% CI 0.05 to 0.09) over the control arm, which showed a change from baseline ranging from 0.03 L to 0.13 L on tiotropium alone. None of the other secondary outcomes (exacerbations, symptom scores, serious adverse events, and withdrawals) showed any statistically significant differences between the groups. There were wide confidence intervals around these outcomes and moderate heterogeneity for both exacerbations and withdrawals.
The results from the one trial comparing the combination of tiotropium and long-acting beta 2 -agonist to long-acting beta 2 -agonist alone (417 participants) were insufficient to draw firm conclusions for this comparison.
Authors' conclusions
The results from this review indicate a small mean improvement in health-related quality of life for patients on a combination of tiotropium and long-acting beta 2 -agonist compared to tiotropium alone, but it is not clear how clinically important this mean difference may be. Hospital admission and mortality have not been shown to be altered by adding long-acting beta 2 -agonists to tiotropium. There were not enough data to determine the relative efficacy and safety of tiotropium plus long-acting beta 2 -agonist compared to long-acting beta 2 -agonist alone. There were insufficient data to make comparisons between the different long-acting beta 2 -agonists when used in addition to tiotropium.
P L A I N L A N G U A G E S U M M A R Y
Is it better to take a combination of tiotropium and long-acting beta 2 -agonists than either inhaler alone for the treatment of COPD?
Chronic obstructive pulmonary disease (COPD) is a lung disease which includes the conditions chronic bronchitis and emphysema. The symptoms include breathlessness and a chronic cough. COPD is an irreversible disease that is usually brought on by airway irritants, such as smoking or inhaled dust.
Long-acting beta 2 -agonists and tiotropium are two types of inhaled medications that help widen the airways (bronchodilators) for up to 12 to 24 hours. These bronchodilators are commonly used to manage persistent symptoms of COPD. They can be used in combination or on their own. These bronchodilators work in different ways and therefore might be more beneficial if used together. The purpose of this review was to determine the benefits and risks of using a combination of both types of bronchodilator compared to the individual bronchodilators.
We found five studies involving 3263 patients comparing the long-term efficacy and side effects of combining tiotropium with a longacting beta 2 -agonist. The combination of tiotropium plus long-acting beta 2 -agonist resulted, on average, in a slightly better quality of life and lung function for the patients compared to using only tiotropium, but did not show a difference in hospital admissions or mortality. There were not enough data to determine the risks and benefits of tiotropium plus long-acting beta 2 -agonist treatment compared to long-acting beta 2 -agonist alone.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
LABA plus tiotropium versus tiotropium for chronic obstructive pulmonary disease 
B A C K G R O U N D Description of the condition
Chronic Obstructive Pulmonary Disease (COPD) is a respiratory disease characterised by chronic and progressive breathlessness, cough, sputum production, and airflow obstruction, which leads to restricted activity and poor quality of life (GOLD). The World Health Organization (WHO) has estimated that COPD is the fourth or fifth most common single cause of death worldwide and the treatment and management costs present a significant burden to public health. In the UK the annual cost of COPD to the National Health Service (NHS) is estimated to be £1.3 million per 100,000 people (NICE 2011) . Furthermore, because of the slow onset and the under-recognition of the disease, it is heavily underdiagnosed (GOLD). COPD comprises a combination of bronchitis and emphysema and involves chronic inflammation and structural changes in the lung. Cigarette smoking is the most important risk factor, however air pollution and occupational dust and chemicals are also recognised risk factors. COPD is a progressive disease leading to decreased lung function over time, even with the best available care. There is currently no cure for COPD, though it is both a preventable and treatable disease. As yet, apart from smoking cessation and non-pharmacological treatments such as long term oxygen therapy in hypoxic patients, no intervention has been shown to reduce mortality (GOLD). Management of the disease is multi-faceted and includes interventions for smoking cessation (van der Meer 2001), pharmacological treatments (GOLD), education (Effing 2007) , and pulmonary rehabilitation (Lacasse 2006) . Pharmacological therapy is aimed at relieving symptoms, improving exercise tolerance and quality of life, slowing decline and even improving lung function, or preventing and treating exacerbations. COPD exacerbations impair patients' quality of life (GOLD). Furthermore, a large part of the economic burden of COPD is attributed to the cost of managing exacerbations, particularly those resulting in use of acute care services or hospitalisations (Hutchinson 2010). In the UK, one in eight emergency admissions to hospital is for COPD, which makes it the second largest cause of emergency admissions and one of the most costly conditions treated by the NHS (NICE 2011). Appropriate pharmacological management of the disease is therefore important to try to reduce and prevent exacerbations.
Description of the intervention
COPD pharmacological management tends to begin with one treatment and additional therapies are introduced, as necessary, to control symptoms (GOLD). The first step is often a short-acting bronchodilator for control of breathlessness when needed, either a short-acting beta 2 -agonist or the short-acting anticholinergic agent ipratropium. For persistent or worsening breathlessness associated with lung function decline, long-acting bronchodilators may be introduced (GOLD). Long-acting bronchodilators include long-acting beta 2 -agonists (LABA), such as salmeterol or formoterol; new ultra long-acting beta 2 -agonist, such as indacaterol; and the long-acting anticholinergic agent tiotropium. For symptomatic patients with severe or very severe COPD (FEV 1 < 50% predicted) and repeated exacerbations, GOLD recommends the addition of inhaled corticosteroids (ICS) to bronchodilator treatment.
How the intervention might work Tiotropium
Tiotropium is an anticholinergic agent which blocks the action of the neurotransmitter acetylcholine. It has an antagonistic effect on muscarinic acetylcholine receptors. Tiotropium has similar affinity for the five different subtypes of muscarinic receptors (M1 to M5), however airway smooth muscle expresses only the M2 and M3 subtypes (Proskocil 2005) . Activation of the M3 receptor stimulates a number of intracellular signalling cascades leading to changes in intracellular Ca 2+ homeostasis and contraction. Tiotropium dissociates slowly from M3 receptors giving a bronchodilator effect lasting over 24 hours, but dissociates rapidly from M2 receptors, which appear to be feedback inhibitory receptors (Barr 2005) . Tiotropium has gained widespread acceptance as a once daily maintenance therapy in stable COPD (Barr 2005; GOLD) for its effects on symptoms and exacerbations. In an early Cochrane review (Barr 2005) tiotropium was shown to reduce the primary endpoint of participants with COPD exacerbations compared to placebo (odds ratio (OR) 0.75; 95% CI 0.66 to 0.85). Within the same review, tiotropium was also associated with a significant benefit over placebo in breathlessness, quality of life, and a reduction in participants with exacerbations that required hospitalisation. Similar effects on symptoms and exacerbations were confirmed in a more recent, large randomised controlled trial of almost 6000 patients who were followed for over four years (Tashkin 2008) . There was, however, no significant effect of tiotropium on lung function decline in this longer study. Anticholinergic side effects that may occur with tiotropium include dry mouth, constipation and tachycardia (Tashkin 2008) . There has been concern expressed about cardiovascular adverse events on tiotropium (Singh 2009), but this was not shown in meta-analysis including the recent UP-LIFT study (Celli 2010).
Long-acting beta 2 -agonists
Inhaled beta 2 -agonists activate beta 2 -receptors in the smooth muscle of the airway leading to a cascade of reactions that result in bronchodilation. Beta 2 -agonists may also act through other mechanisms such as respiratory muscle function or mucociliary clearance because patients have shown improvements in symptoms whilst showing no improvement in lung function tests. Beta 2 -agonists are particularly useful bronchodilators because they reverse bronchoconstriction regardless of the initial cause. The commonly used long-acting beta 2 -agonists salmeterol and formoterol and the ultra long-acting beta 2 -agonist indacaterol all have a higher selectivity for beta 2 -receptors than beta 1 -receptors (Moen 2010; Wallukat 2002) . Beta 2 -receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -receptors are the predominant receptors in the heart, although 10% to 50% of the total betareceptors in the heart are comprised of beta 2 -receptors. The presence of beta 2 -receptors in the heart raises the possibility that even highly selective beta 2 -agonists may have cardiac effects. The duration of action for salmeterol and formoterol is approximately 12 hours, and they are therefore usually taken twice daily. Indacaterol has a duration of action of 24 hours and can, therefore, be taken once daily. The mechanism for activating beta 2 -receptors differs between these long-acting beta 2 -agonists. Formoterol is taken up into a membrane depot from where it gradually leaks out to interact with the receptor, whilst salmeterol binds near the receptor, allowing it to remain at the receptor site continually binding and releasing (Johnson 1998) . Indacaterol has a higher affinity to lipid domains within the membrane than salmeterol, which may potentially explain its prolonged duration of action (Beier 2011). Independent of long-acting beta 2 -agonist (LABA) type, stimulation of the beta 2 -receptors leads to changes in intracellular Ca 2+ homeostasis and bronchodilation (Tanaka 2005) . As with tiotropium, LABAs are used as 'symptom controllers' in stable COPD. A prior Cochrane review found that salmeterol improves lung function compared to placebo (Appleton 2006) . A more recent, large (3045 patients), long-term (three-year) randomised control trial also compared salmeterol to placebo (TORCH) (Calverley 2007) . In this trial salmeterol use was associated with an increase in lung function and a significant reduction in the annual rate of moderate or severe exacerbations compared with placebo (rate ratio 0.85, P < 0.001). A systematic review, which included the TORCH study and another 13 trials looking at salmeterol or formoterol (6453 participants), showed that treatment with a LABA reduced the rate of exacerbations and improved lung function and quality of life compared to placebo, but had no significant effect on mortality (Rodrigo 2008 
Why it is important to do this review
Both tiotropium and long-acting beta 2 -agonists are recommended for treatment of stable COPD (GOLD). However, patients whose COPD is not adequately managed by either LABA or tiotropium treatment alone could potentially benefit from treatment with a combination of the two. It has been suggested that combination therapies directed at both adrenergic and muscarinic receptors could provide greater, and potentially additive, bronchodilation compared with a beta 2 -agonist or a muscarinic antagonist alone (Proskocil 2005) . A number of trials have been published looking at the effect of adding tiotropium to LABA for treatment of COPD, and the clinical evidence to date suggests there may be benefits in combining the treatments without increasing side effects (Cazzola 2010). This review is necessary to specify and quantify the potential benefits from the combination treatment with LABA and tiotropium compared to the individual components alone. This review will form part of a suite of reviews on the various combinations of tiotropium, long-acting beta 2 -agonists and inhaled corticosteroids for the treatment of COPD. These reviews will ultimately be summarised in an overview. The first two of these reviews compared a combination of inhaled corticosteroids and long-acting beta 2 -agonists with tiotropium (Welsh 2010) and triple therapy (inhaled corticosteroids, long-acting beta 2 -agonist and tiotropium) with either tiotropium alone or inhaled corticosteroid (ICS) and LABA combination therapy (Karner 2011). Further reviews are in preparation comparing alternate permutations of these three drugs.
O B J E C T I V E S
To compare the relative effects on markers of quality of life, exacerbations, symptoms, lung function and serious adverse events in patients with chronic obstructive pulmonary disease randomised to the following therapies:
• long-acting beta 2 -agonists and tiotropium versus longacting beta 2 -agonists alone; or
• long-acting beta 2 -agonists and tiotropium versus tiotropium alone.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised trials (RCTs) with a parallel group design of at least 12 weeks duration. We did not exclude studies on the basis of blinding.
Types of participants
We included populations with a diagnosis of chronic obstructive pulmonary disease. We only included studies where an external set of criteria had been used to screen participants for this condition (for example the Global initiative for chronic Obstructive Lung Disease (GOLD), American Thoracic Society (ATS), British Thoracic Society (BTS), Thoracic Society of Australia and New Zealand (TSANZ)).
Types of interventions
We included participants who were randomised to receive inhaled long-acting beta 2 -agonist in addition to tiotropium bromide compared to those on either inhaled tiotropium bromide alone or inhaled long-acting beta 2 -agonist alone. We allowed any formulation of long-acting beta 2 -agonists and tiotropium bromide. Participants were allowed inhaled steroids and other co-medications provided they were not part of the randomised treatment. 
Types of outcome measures

Data collection and analysis
Selection of studies
Two review authors screened the titles and abstracts of citations retrieved through literature searches and obtained those deemed to be potentially relevant. We assigned each reference to a study identifier and independently assessed them against the inclusion criteria of this review.
Data extraction and management
We extracted information from each study for the following characteristics. 1. Design (design, total study duration and run-in, number of study centres and location, withdrawals, date of study).
2. Participants (N, mean age, age range, gender, COPD severity, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, exclusion criteria).
3. Interventions (run-in, intervention treatment and inhaler type, control treatment and inhaler type).
4. Outcomes (primary and secondary outcomes specified and collected, time points reported). Two authors extracted data from the studies into data collection forms. We discussed and resolved any discrepancies in the data, or consulted a third party where necessary. We transferred data from the data collection forms into Review Manager 5.
Assessment of risk of bias in included studies
We assessed the risk of bias according to recommendations outlined in the Cochrane Handbook for Systematic reviews of Interventions (Higgins 2008) for the following items.
1. Allocation sequence generation.
2. Concealment of allocation. 3. Blinding of participants and investigators. 4. Incomplete outcome data. 5. Selective outcome reporting. We noted other sources of bias. We graded each potential source of bias as low, high or unclear risk of bias.
Measures of treatment effect
Dichotomous data
We analysed dichotomous data variables (such as mortality and withdrawals) using odds ratios (OR). If count data were not available as the number of participants experiencing an event, we analysed the data as continuous, time-to-event or rate ratios, depending on how they were reported. This includes the outcomes: hospital admissions, exacerbations, and serious adverse events.
Continuous data
We analysed continuous outcome data (such as FEV 1 and quality of life) as fixed-effect model mean differences (MD) when the same scale was used, and standardised mean differences when different scales were employed in different studies. Mean difference based on the change from baseline was preferred over mean difference based on absolute values. If data were not available for the same time point in all studies, we used the closest time points. Alternatively, end of study was used as a time of analysis for all studies. We used intention-totreat (ITT) analysis on outcomes from all randomised participants, where possible, for primary analyses.
Unit of analysis issues
We analysed dichotomous data using participants as the unit of analysis (rather than events) to avoid counting the same participant more than once.
Dealing with missing data
We contacted investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data, where possible. We also considered the impact of the unknown status of participants who withdrew from the trials as part of the sensitivity analysis.
Assessment of heterogeneity
We assessed the amount of statistical variation between the study results with the I 2 statistic measurement.
Assessment of reporting biases
We minimised reporting bias from non-publication of studies or selective outcome reporting by using a broad search strategy, contacting study authors directly and checking references of included studies. If we had found sufficient numbers of trials, we planned to visually inspect funnel plots.
Data synthesis
We combined dichotomous data using Mantel-Haenzsel odds ratios with 95% confidence intervals, with a fixed-effect model. Where events were rare, we employed the Peto odds ratio (OR) (since this does not require a continuity correction for zero cells). Where treatment effects were reported as a mean difference with 95% confidence interval or exact P value, we calculated the standard error, entered it with the mean difference (MD) and combined the results using a fixed effect Generic Inverse Variance (GIV) model in Review Manager 5. Rate ratios and hazard ratios were combined using a fixed-effect GIV model. Numbers needed to treat would have been calculated from the pooled odds ratio and its confidence interval (CI), and applied to appropriate levels of baseline risk. We presented the findings of our primary outcomes in a summary of findings table using GradePro software and recommendations in the Handbook for Systematic Reviews of Interventions (Higgins 2008) .
Subgroup analysis and investigation of heterogeneity
Studies were subgrouped, where possible, according to:
1. type of long-acting beta-agonist; 2. severity of disease at baseline; and 3. tiotropium formulation.
Sensitivity analysis
We assessed the sensitivity of our primary outcomes to degree of bias by comparing the overall results with those exclusively from trials assessed as being at low risk of bias. We also compared the results from the fixed-effect models with results from randomeffects models.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.
Results of the search
The database search identified 172 references in September 2011 and an additional five references in January 2012. Of these we identified 27 as potentially relevant, which we obtained in full text for further assessment. Fifteen of these were eligible and belonged to five studies ( 
Sample size
There were 3473 participants randomised to the relevant treatment arms in the included studies: LABA + tiotropium (1621), tiotropium (1642), and LABA (210).
Participants
The mean age of participants varied from 63 to 68 years. The gender distribution varied from 54% to 79% males. All studies included participants with moderate to severe COPD, although Aaron 2007 and Vogelmeier 2008 also included patients with very severe COPD (FEV 1 less than 30% predicted) according to GOLD guideline definitions of COPD. The mean baseline lung function varied between 38% and 52% predicted across the studies.
Interventions
All included studies used 18 µg of tiotropium (Handihaler), one inhalation daily. In Aaron 2007 the LABA used was salmeterol 25 µg/puff, two puffs twice daily using a pressurized metereddose inhaler and a spacer device. Both 
Permitted co-treatment
In all five studies participants were allowed to use inhaled salbutamol, when necessary, to relieve symptoms. Mahler 2010a, Mahler 2010b, Tashkin 2009 and Vogelmeier 2008 permitted continued use of regimens of inhaled corticosteroid that were stable prior to entry throughout the study. In Aaron 2007 respiratory medications such as oxygen, antileukotrienes, and methylxanthines were continued in all patient groups.
Outcomes
The primary outcome for Aaron 2007 was the proportion of patients suffering one or more COPD exacerbations. The primary outcome for Vogelmeier 2008 was FEV 1 measured two hours postdose at the end of the study. In Tashkin 2009 the primary outcome was also post-dose FEV 1 , but the normalised area under the curve for FEV 1 measured from zero to four hours post-morning dose at the last visit. 
Excluded studies
Eleven studies failed to meet the eligibility criteria for the review (see Characteristics of excluded studies). Seven of these compared tiotropium alone with a long-acting beta 2 -agonist but had no treatment arm with a combination of the two ( 
Risk of bias in included studies
An assessment of the risk of bias is presented in the Characteristics of included studies table, and an overview of the findings is shown in (Figure 2 ). 
Allocation
All three studies reported adequate sequence generation, through a computer generated system, and allocation concealment. Information from Vogelmeier 2008 was kindly supplied on request. In Aaron 2007 and Vogelmeier 2008 randomisation data were kept strictly confidential until the time of unblinding, and was not accessible by anyone involved in the study before or after randomisation. In Tashkin 2009 the randomisation code was labelled on the medication kit.
Blinding
The blinding in Aaron 2007 was adequate. In Aaron 2007 both research staff and patients were blinded to the treatment assignment until the end of the study. The different inhalers were identical and they were enclosed in tamper-proof blinding devices. Clinical data for suspected exacerbations were reviewed by a blinded committee and the statistician who performed the analysis was initially blinded to patient group assignments. The Vogelmeier 2008 study was partially blinded with tiotropium being administered open-label, but double-blind for the long-acting beta 2 -agonist treatment. The risk of performance bias was therefore high for the comparison LABA + tiotropium versus LABA, and low for LABA + tiotropium versus tiotropium. The risk of detection bias was also low as outcome assessors and data analysts were blinded to patient group assignments. Information from Vogelmeier 2008 was kindly supplied on request. Tashkin 2009 did not fully describe in the study report who was blinded.
Incomplete outcome data
Aaron 2007 suffered from high withdrawal rates in the different study groups (74 patients (47%) withdrew from the tiotropium + placebo group and 64 patients (43%) on LABA + tiotropium). For most patients, data were recorded throughout the one-year trial period regardless of whether patients discontinued treatment with study medications. The rates of patients who stopped therapy and did not complete the trial were 30 patients (19%) on tiotropium + placebo and 20 patients (14%) on LABA + tiotropium. Mortality data were obtained for all participants with the exception of two out of 148 participants (1.4%) on LABA + tiotropium and four out of 156 participants (2.6%) on tiotropium + placebo, who withdrew and declined further study. In Tashkin 2009 the number of withdrawals was also uneven but was relatively low (LABA + tiotropium (14.5%), and tiotropium + placebo (6.1%)). In the other three studies the number of withdrawals in the different groups were relatively low and even (Mahler 2010a: LABA + tiotropium (6.8%) and tiotropium + placebo (6.2%); Mahler 2010b: LABA + tiotropium (5.1%) and tiotropium + placebo (6.5%); Vogelmeier 2008: LABA + tiotropium (12%), LABA (12%) and tiotropium + placebo (13%)).
Selective reporting
All the included studies adequately reported outcome data for the primary and secondary outcomes that they had pre-specified in the study records, but we did not compare reported outcomes to the trial protocols.
Effects of interventions
See: Summary of findings for the main comparison LABA plus tiotropium versus tiotropium for chronic obstructive pulmonary disease
LABA plus tiotropium versus tiotropium
We planned to analyse the data using subgroups for disease severity, type of long-acting beta 2 -agonist, and tiotropium formulation. We subgrouped the data in the forest plots according to type of long-acting beta 2 -agonist. However, these need to be interpreted with caution because of the small number of trials and the many significant differences between them, including length of study.
Primary outcome: quality of life
Two studies (729 participants) looked at changes in quality of life using the St George's Respiratory Questionnaire (SGRQ); Aaron 2007 added salmeterol to tiotropium and Vogelmeier 2008 added formoterol to tiotropium. A decrease in SGRQ score denotes an improvement in quality of life and a difference of at least four units is regarded as clinically significant (SGRQ-C manual 2008). Aaron 2007 showed an improvement in quality of life in the control arm, tiotropium alone, of -4.5 units after one year. The pooled result of the treatment difference between LABA + tiotropium and tiotropium alone showed that the combination treatment led to -6.1 unit improvement in quality of life. This difference was significantly larger (statistically) than with tiotropium alone (MD -1.61; 95% CI -2.93 to -0.29), see Figure 3 . The confidence interval of this mean difference excludes the minimal clinically important difference of four units but there is additional uncertainty in relation to the quality of life in those patients who withdrew from the study. The number of hospitalised patients were similar and there was no statistically significant difference between the treatment groups for hospitalisations for any cause (OR 1.01; 95% CI 0.63 to 1.61) or due to exacerbation (OR 1.07; 95% CI 0.63 to 1.81). There was a wide confidence interval for the result as the total number of participants with an event was low, and there was additional uncertainty arising from the potential additional admissions that were not known in the patients who withdrew. See Figure 4 and Figure 5 respectively. 
Secondary outcome: exacerbations
Three studies (987 participants), on formoterol and salmeterol, reported the number of patients suffering one or more exacerbation during the study period (Aaron 2007; Tashkin 2009; Vogelmeier 2008) . Aaron 2007 defined exacerbations as a sustained worsening of the patient's respiratory condition, from the stable state and beyond normal day-to-day variations, necessitating a change in regular medication in a patient with underlying COPD. Vogelmeier 2008 reported the number of patients suffering COPD exacerbations who required additional therapy, defined as COPD-related adverse events (AEs) requiring additional therapy, where COPDrelated AEs were defined as AEs coding to the preferred terms: COPD, COPD exacerbated, cough, any term containing 'dyspnoea', lower respiratory tract infection, chronic bronchitis, bronchospasm, bronchial obstruction and respiratory failure; and additional therapy was any COPD therapy reported as being used to treat a COPD exacerbation, other than rescue bronchodilator. In Tashkin 2009 the definition of exacerbation was not described, but it was stated that most patients who needed treatment for their exacerbations received antibiotics alone or a course of antibiotics and systemic steroids. The baseline risk also varied greatly between the studies. In the one-year study (Aaron 2007) 62.8% of patients on tiotropium alone experienced one or more exacerbations, whereas in Tashkin 2009 and Vogelmeier 2008 the number was 10.7% and 10.4%, respectively. There was also substantial heterogeneity between the studies (I 2 = 55%) and the exacerbation status of the patients who withdrew from each study was unknown. In Tashkin 
Secondary outcome: withdrawal
All five studies (3263 participants) reported the number of withdrawals from study medication in each treatment group. Most of the studies had relatively even withdrawal rates and there was no statistically significant difference between the treatment groups (OR 1.00; 95% CI 0.74 to 1.37). The exception was Tashkin 2009 (LABA + tiotropium 12%, tiotropium alone 6%), which introduced moderate heterogeneity in the pooled result (I 2 = 38%).
LABA plus tiotropium versus LABA
Vogelmeier 2008 was the only eligible study identified that compared LABA + tiotropium versus LABA (417 patients). The study was not blinded for this comparison for any of the outcomes as tiotropium was administered open-label. The LABA used in Vogelmeier 2008 was formoterol. The study reported the following results for outcomes of interest for this review.
Primary outcomes
For the primary outcomes there were no significant differences between the treatments for quality of life (SGRQ, MD 0.00; 95% CI -2.70 to 2.70) and the number of patients admitted to hospital for any cause (OR 1.02; 95% CI 0.37 to 2.76) (data kindly supplied by Vogelmeier 2008). There were, however, fewer patients admitted to hospital for an exacerbation in the formoterol + tiotropium group (3 people out of 207) compared to the formoterol group (9 people out of 221), but the number of events was low and the confidence intervals were wide (OR 0.35; 95% CI 0.09 to 1.30). There were no deaths reported in either of the treatment groups.
Secondary outcomes
For all of the secondary outcomes, there were wide confidence intervals and no statistically significant difference between formoterol + tiotropium and formoterol alone 
D I S C U S S I O N Summary of main results
This systematic review set out to investigate the long-term (three months or longer) effects of tiotropium in combination with LABA compared to either LABA alone or tiotropium alone, for the treatment of COPD. Five randomised, parallel group, placebocontrolled trials with 3473 participants were identified. All five studied the effects of tiotropium in combination with LABA compared to tiotropium alone, whereas only one of these studies (Vogelmeier 2008, 417 participants) also looked at tiotropium in combination with LABA compared to LABA alone.
LABA plus tiotropium versus tiotropium
This review found that compared to tiotropium alone, treatment with tiotropium plus long-acting beta 2 -agonist resulted in a slightly larger improvement in the mean health-related quality of life (SGRQ, MD -1.61; 95% CI -2.93 to -0.29). This represented a change from baseline of -6.1 units with both treatments compared to tiotropium alone, which improved by -4.5 units from baseline. This mean improvement was small in relation to the threshold of four units for a clinically significant difference. No significant differences were found in the other primary outcomes (hospital admissions and mortality). Pre-bronchodilator FEV 1 also showed a statistically significant improvement with LABA + tiotropium compared to tiotropium alone. None of the other secondary outcomes (exacerbations, symptom scores, serious adverse events, and withdrawals) showed any statistically significant difference between the groups. There were, however, wide confidence intervals regarding the results for all outcomes and moderate heterogeneity for both exacerbations and withdrawals.
LABA plus tiotropium versus LABA
The study looking at the effect of formoterol + tiotropium versus formoterol (Vogelmeier 2008, 417 participants) showed very wide confidence intervals and no statistically significant difference between the treatment groups for any of the relevant outcomes reported: health-related quality of life, hospitalisations (all-cause and due to exacerbations), mortality (there were no deaths during the study period in either group), exacerbations, FEV 1 , symptom scores, serious adverse events or withdrawals. The fact that only one study, with a relatively small total number of participants, was included in this review makes the result for outcomes with few events or small differences less reliable.
Overall completeness and applicability of evidence
The lack of clear differences in effect between the treatment groups for many of the outcomes may be due to the relatively short treatment duration, with four out of five studies being shorter than one year. This led to few events, wide confidence intervals and low power to detect any differences. For continuous outcomes such as lung function, quality of life and symptom scores, studies with a duration of less than six months may not provide enough time to reach a steady state, which may also influence the result in a conservative way. The results from this review indicate a small improvement in the mean health-related quality of life and lung function for patients on a combination of LABA and tiotropium compared to tiotropium alone. The mean improvement for both outcomes was statistically significant but relatively small in relation to the minimum clinically important difference for each outcome. However, there may still be a significant number of patients who have a clinically relevant improvement compared to the number with a clinically relevant deterioration. This kind of responder analysis may be a useful additional way of measuring health-related quality of life.
Quality of the evidence
We encountered heterogeneity in the outcomes COPD exacerbations and the number of patients withdrawing from the studies. This could be from one or more of several sources, such as the differences in definition of exacerbation and the length of the studies. The smallest study (Tashkin 2009, 255 participants) had more uneven withdrawal rates compared with the other studies.
Agreements and disagreements with other studies or reviews
In addition to the long-term (three months or longer duration) studies presented in this review there have been several studies looking at acute and short-term (up to six weeks) effects of tiotropium + LABA compared to tiotropium or LABA alone (Cazzola 2010). One short-term, parallel group study also looked at health-related quality of life using the SGRQ (Tashkin 2008a). After six weeks treatment they found no difference between tiotropium + LABA compared to tiotropium alone. However, at least for LABA it may take up to six months of treatment to reach a steady state and to see the full effect on quality of life (Calverley 2007).
Cost effectiveness
The cost effectiveness of tiotropium + LABA treatment compared to both tiotropium alone and triple therapy consisting of ICS and LABA combination inhaler + tiotropium has been assessed for the Aaron 2007 study (Najafzadeh 2008). The setting for this one-year study was within the Canadian healthcare system and the cost effectiveness evaluation was based on 2006 prices. In this study, treatment with tiotropium + LABA resulted in both higher costs and a higher rate of exacerbations than treatment with tiotropium alone. However, when focusing on patients with severe COPD tiotropium + LABA resulted in equal exacerbation rates and slightly lower costs compared to tiotropium alone, although there was considerable uncertainty around this result. Therefore, based on Aaron 2007, tiotropium on its own is the most cost effective treatment compared to tiotropium + LABA when looking at the incremental cost for exacerbations avoided and per additional quality adjusted life year. However, for a chronic illness like COPD a cost effectiveness study of one year is unlikely to capture all relevant costs and benefits.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Implications for research
Additional long-term (12 months or longer) larger studies are needed to clarify the risks and benefits of tiotropium + LABA treatment compared to the individual drugs. If the number of participants is large enough this will enable analysis to assess the suitability of this combination of therapies for patients with different severities of COPD. For quality of life measurements in future studies, it may be beneficial to use both mean changes with 95% confidence intervals and responders analysis. However, the responders analysis would preferably include both the number of people who have a clinically meaningful improvement as well as the number of people who have a clinically meaningful worsening. Presenting just one side of the data distribution, as in the percentage of patients with a clinically meaningful improvement, is becoming more common but is of limited value.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aaron 2007
Methods
Design: A randomised, double-blind, placebo-controlled, parallel group trial from October 2003 to January 2006. The trial included 27 Canadian medical centres; 20 centres were academic hospital-based pulmonary clinics, 5 were community-based pulmonary clinics, and 2 were community-based primary care clinics Participants Population: 304 adults, with a clinical history of moderate or severe COPD as defined by ATS and GOLD guidelines, were randomised to tiotropium + salmeterol (148) and tiotropium (156) Baseline Characteristics: Mean age 68 years. COPD severity moderate to severe with mean FEV 1 predicted of 38%. 57% men. Inclusion Criteria: At least 1 exacerbation of COPD that required treatment with systemic steroids or antibiotics within the 12 months before randomisation; age older than 35 years; a history of 10 pack-years or more of cigarette smoking; documented chronic airflow obstruction, with an FEV 1 /FVC ratio less than 0.70 and a post-bronchodilator FEV 1 less than 65% of the predicted value. Exclusion Criteria: History of physician-diagnosed asthma before 40 years of age; history of physician-diagnosed chronic congestive heart failure with known persistent severe left ventricular dysfunction; those receiving oral prednisone; those with a known hypersensitivity or intolerance to tiotropium, salmeterol, or fluticasone-salmeterol; history of severe glaucoma or severe urinary tract obstruction, previous lung transplantation or lung volume reduction surgery, or diffuse bilateral bronchiectasis; and those who were pregnant or were breastfeeding Interventions 1. Tiotropium + salmeterol: tiotropium 18 µg once daily using a Handihaler plus salmeterol 25 µg/puff, 2 puffs twice daily using a pressurized metered-dose inhaler using a spacer device 2. Tiotropium + placebo: tiotropium, 18 µg once daily, plus placebo inhaler, 2 puffs twice daily Outcomes Primary: Proportion of patients with one or more exacerbation of COPD Secondary: Mean number of COPD exacerbations per patient-year; the total number of exacerbations that resulted in urgent visits to a health care provider or emergency department; the number of hospitalizations for COPD; the total number of hospitalizations for all causes; changes in health-related quality of life, dyspnoea, lung function Notes Co-medication: All study patients were provided with inhaled albuterol and were instructed to use it when necessary to relieve symptoms. Any treatment with inhaled corticosteroids, long-acting 2-agonists, and anticholinergics that the patient may have been using before entry was discontinued on entry into the study. Therapy with other respiratory medications, such as oxygen, antileukotrienes, and methylxanthines, was continued in all patient groups Low risk Neither research staff nor patients were aware of the treatment assignment before or after randomisation. The metereddose inhalers containing placebo, salmeterol, and fluticasone-salmeterol were identical in taste and appearance, and they were enclosed in identical tamper-proof blinding devices. The medication canisters within the blinding devices were stripped of any identifying labelling
Blinding of outcome assessment (detection bias) Exacerbations
Low risk The assembled data from the visit for the suspected exacerbation were presented to a blinded adjudication committee for review, and the committee confirmed whether the encounter met the study definition of COPD exacerbation
Incomplete outcome data (attrition bias) All outcomes
Unclear risk
The number of people who stopped drug therapy was high in both groups. 74 patients (47%) withdrew from the tiotropium + placebo group and 64 patients (43%) on LABA + tiotropium group. However, the number of people who did not complete the trial was lower (30 patients (19%) on tiotropium + placebo and 20 patients (14%) on LABA + tiotropium). The incomplete data were however addressed by sensitivity analyses of the data comprising alternative assumptions for patients who prematurely withdrew from treatment Selective reporting (reporting bias) Low risk Results for all listed primary and secondary outcomes were reported
Mahler 2010a
Methods Design: A multi-centre, multi-national, randomised, double-blind, parallel-group study from March 2009 to March 2010. The trial included 186 study centres in 14 countries: Argentina (10), Australia (6), Colombia (5), Denmark (5), Germany (25), Greece (4) , Guatemala (5), Mexico (5), Peru (6), Philippines (2), South Africa (6), Spain (13), Turkey (13), and USA (81) Participants Population: 1134 patients with a clinical history of moderate or severe COPD as defined by GOLD guidelines, were randomised to tiotropium + indacaterol (570) 
Risk of bias
Bias
Authors' judgement Support for judgement
Random sequence generation (selection bias)
Low risk A patient randomisation list was produced by the IVRS provider using a validated system that automates the random assignment of patient numbers to randomisation numbers Allocation concealment (selection bias) Low risk The randomisation numbers were linked to the different treatment arms, which in Mahler 2010a (Continued) turn were linked to medication numbers. A separate medication randomisation list was produced by or under the responsibility of Novartis Drug Supply Management using a validated system that automates the random assignment of medication numbers to medication packs containing each of the study drugs
Blinding of participants and personnel (LABA+TIO versus TIO) (performance bias)
Low risk Patients, investigator staff, persons performing the assessments, data analysts and the Novartis trial team were all blinded
Blinding of outcome assessment (detection bias) Exacerbations
Low risk Persons performing the assessments were blinded.
Low risk
The withdrawal rates were low and even (tiotropium + indacaterol 6.8%, tiotropium 6.2%)
Selective reporting (reporting bias) Low risk Results for all listed primary and secondary outcomes were reported
Mahler 2010b
Methods Design: A multi-centre, multi-national, randomised, double-blind, parallel-group study from April 2009 to February 2010. The trial included 182 study centres in 11 countries: Argentina (9), Canada (16), Colombia (3), Czech Republic (9), Hungary (4), India (9) , Netherlands (6), Philippines (3), Slovakia (10), Spain (11), and USA (102) Participants Population: 1142 patients with a clinical history of moderate or severe COPD as defined by GOLD guidelines, were randomised to tiotropium + indacaterol (572) and tiotropium (570) Baseline Characteristics: Mean age 63 years, 65% male, mean FEV 1 1.3 L, mean FEV 1 predicted 49%, 46 pack-years smoking history. Inclusion Criteria: Men and women aged ≥40 years with moderate-to-severe COPD, with a smoking history ≥10 pack-years and post-bronchodilator FEV 1 ≤ 65% and ≥ 30% predicted and FEV 1 /FVC < 70%. Exclusion Criteria: Patients who have received systematic corticosteroids and/or antibiotics and/or was hospitalised for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period or had a respiratory tract infection within 6 weeks prior to screening. Patients with concomitant pulmonary disease, a history of asthma, diabetes Type I or uncontrolled diabetes Type II, lung cancer or a history of lung cancer, a history of certain cardiovascular comorbid conditions Interventions 1. Indacaterol 150 µg through single-dose dry powder inhaler (SDDPI), once daily + tiotropium 18 µg through SDDPI Handihaler, once daily 2. Placebo to indacaterol + tiotropium 18 µg through SDDPI Handihaler, once daily 
Risk of bias
Bias
Authors' judgement Support for judgement
Low risk A patient randomisation list was produced by the IVRS provider using a validated system that automates the random assignment of patient numbers to randomisation numbers Allocation concealment (selection bias) Low risk The randomisation numbers were linked to the different treatment arms, which in turn were linked to medication numbers. A separate medication randomisation list was produced by or under the responsibility of Novartis Drug Supply Management using a validated system that automates the random assignment of medication numbers to medication packs containing each of the study drugs
Blinding of outcome assessment (detection bias) Exacerbations
Low risk
The withdrawal rates were low and even (tiotropium + indacaterol 5.1%, tiotropium 6.5%)
Selective reporting (reporting bias) Low risk Results for all listed primary and secondary outcomes were reported 
Tashkin 2009
Methods Design: A randomised, double-blind, active-control, parallel group trial. The trial included 35 centres across the United States, of which the majority were primary care centres Participants Population: 255 adults with a clinical history of COPD were randomised to tiotropium + formoterol (124) and tiotropium (131) Baseline Characteristics: Mean age 64 years. COPD severity mild to severe. 67% men. Inclusion Criteria: Male and non-pregnant female patients aged >40 years who had a clinical history of COPD were enrolled in this study. Each patient had a post-bronchodilator FEV1 < 70% and >30% predicted normal or >0.75 L, whichever was less, at run-in, and a FEV 1 to FVC ratio (FEV 1 /FVC) of < 0.70 at screening and run-in. Daytime and/or nighttime symptoms of COPD, including dyspnoea, must have been present on ≥4 of the 7 days before the baseline visit Exclusion Criteria: A current or previous history of asthma or other significant medical condition that may have interfered with study treatment as assessed by the investigator, smoking cessation within the previous 3 months, ventilator support for respiratory failure within the previous year, the use of oxygen (≥2 L/min or for >2 h/d), initiation of pulmonary rehabilitation within the previous 3 months, the requirement for nasal continuous positive airway pressure or bilevel positive airway pressure, clinically significant lung disease other than COPD (i.e., bronchiectasis, sarcoidosis, pulmonary fibrosis, tuberculosis), sleep apnoea, chronic narrow-angle glaucoma, symptomatic prostatic hyperplasia or bladder neck obstruction, and the need for chronic or prophylactic antibiotic therapy (9), Russian federation (9), Poland (7), Czech Republic (4), Spain (4) and Hungary (4) Participants Population: 638 adults, with a clinical history of moderate to very severe COPD as defined by GOLD guidelines, were randomised to tiotropium + formoterol (207), formoterol (210), and tiotropium (221) Baseline Characteristics: Mean age 63 years. COPD severity moderate to very severe with mean FEV 1 predicted of 52%. 78% men. Inclusion Criteria: Males and females with stable COPD aged ≥40 years at COPD onset and with a smoking history of ≥10 pack-years, forced expiratory volume in 1 second (FEV 1 ) < 70% of patient's predicted normal value (and ≥1.00 L), and FEV 1 / forced vital capacity (FVC) < 70%. They were to be symptomatic on at least 4 of 7 days prior to randomisation (symptom score >0 on diary card) Exclusion Criteria: Patients who had a respiratory tract infection or had been hospitalised for an acute exacerbation of COPD within the month prior to screening. Patients with a clinically significant condition such as ischaemic heart disease that might com- Low risk A randomisation list was produced using a validated system that automates the random assignment of treatment groups to randomisation numbers in the specified ratio. Review: Long-acting beta 2 -agonist in addition to tiotropium versus either tiotropium or long-acting beta 2 -agonist alone for chronic obstructive pulmonary disease Review: Long-acting beta 2 -agonist in addition to tiotropium versus either tiotropium or long-acting beta 2 -agonist alone for chronic obstructive pulmonary disease Review: Long-acting beta 2 -agonist in addition to tiotropium versus either tiotropium or long-acting beta 2 -agonist alone for chronic obstructive pulmonary disease Review: Long-acting beta 2 -agonist in addition to tiotropium versus either tiotropium or long-acting beta 2 -agonist alone for chronic obstructive pulmonary disease Review: Long-acting beta 2 -agonist in addition to tiotropium versus either tiotropium or long-acting beta 2 -agonist alone for chronic obstructive pulmonary disease 
